Regenxbio Accounts Payable vs Deferred Long Term Liab Analysis

RGNX Stock  USD 10.01  0.46  4.82%   
Regenxbio financial indicator trend analysis is much more than just breaking down Regenxbio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regenxbio is a good investment. Please check the relationship between Regenxbio Accounts Payable and its Deferred Long Term Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Accounts Payable vs Deferred Long Term Liab

Accounts Payable vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regenxbio Accounts Payable account and Deferred Long Term Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Regenxbio's Accounts Payable and Deferred Long Term Liab is 0.56. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Regenxbio, assuming nothing else is changed. The correlation between historical values of Regenxbio's Accounts Payable and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Regenxbio are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Accounts Payable i.e., Regenxbio's Accounts Payable and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.56
Relationship DirectionPositive 
Relationship StrengthWeak

Accounts Payable

An accounting item on the balance sheet that represents Regenxbio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regenxbio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.
Most indicators from Regenxbio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.Sales General And Administrative To Revenue is likely to rise to 1.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 47.8 M in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit418.5M58.2M53.0M91.4M
Total Revenue470.3M112.7M90.2M111.6M

Regenxbio fundamental ratios Correlations

0.860.840.830.960.75-0.58-0.540.710.790.950.960.84-0.630.890.750.920.890.960.53-0.630.950.680.610.680.89
0.860.950.940.70.45-0.33-0.750.870.640.830.790.78-0.470.790.880.870.980.810.76-0.470.780.390.430.590.91
0.840.951.00.720.46-0.22-0.830.920.550.830.770.74-0.480.80.980.860.90.790.84-0.480.80.440.460.60.98
0.830.941.00.710.45-0.18-0.850.940.510.820.760.73-0.490.80.980.860.890.780.86-0.490.80.430.420.630.97
0.960.70.720.710.82-0.55-0.430.60.720.920.930.76-0.670.860.650.870.730.930.42-0.670.960.770.60.690.81
0.750.450.460.450.82-0.5-0.170.340.570.740.70.69-0.590.690.360.670.50.70.14-0.590.740.460.590.50.56
-0.58-0.33-0.22-0.18-0.55-0.5-0.20.07-0.93-0.48-0.63-0.530.29-0.35-0.07-0.32-0.51-0.610.260.29-0.42-0.33-0.620.02-0.29
-0.54-0.75-0.83-0.85-0.43-0.17-0.2-0.93-0.14-0.46-0.54-0.550.48-0.68-0.88-0.73-0.63-0.56-0.970.48-0.6-0.30.04-0.66-0.81
0.710.870.920.940.60.340.07-0.930.280.670.660.64-0.490.760.910.830.770.680.95-0.490.70.410.120.740.88
0.790.640.550.510.720.57-0.93-0.140.280.70.810.73-0.410.580.410.580.780.810.09-0.410.640.420.670.20.59
0.950.830.830.820.920.74-0.48-0.460.670.70.830.7-0.530.80.760.850.840.840.5-0.530.910.580.730.570.86
0.960.790.770.760.930.7-0.63-0.540.660.810.830.88-0.670.90.660.90.841.00.49-0.670.920.740.450.710.84
0.840.780.740.730.760.69-0.53-0.550.640.730.70.88-0.50.80.630.820.830.90.49-0.50.780.530.340.650.76
-0.63-0.47-0.48-0.49-0.67-0.590.290.48-0.49-0.41-0.53-0.67-0.5-0.66-0.45-0.65-0.44-0.67-0.481.0-0.69-0.47-0.17-0.54-0.57
0.890.790.80.80.860.69-0.35-0.680.760.580.80.90.8-0.660.740.980.780.910.62-0.660.910.710.370.830.88
0.750.880.980.980.650.36-0.07-0.880.910.410.760.660.63-0.450.740.80.80.690.88-0.450.760.390.410.580.95
0.920.870.860.860.870.67-0.32-0.730.830.580.850.90.82-0.650.980.80.850.910.69-0.650.940.670.390.840.91
0.890.980.90.890.730.5-0.51-0.630.770.780.840.840.83-0.440.780.80.850.860.62-0.440.770.420.50.530.87
0.960.810.790.780.930.7-0.61-0.560.680.810.841.00.9-0.670.910.690.910.860.52-0.670.920.720.450.720.85
0.530.760.840.860.420.140.26-0.970.950.090.50.490.49-0.480.620.880.690.620.52-0.480.570.3-0.040.650.79
-0.63-0.47-0.48-0.49-0.67-0.590.290.48-0.49-0.41-0.53-0.67-0.51.0-0.66-0.45-0.65-0.44-0.67-0.48-0.69-0.47-0.17-0.54-0.57
0.950.780.80.80.960.74-0.42-0.60.70.640.910.920.78-0.690.910.760.940.770.920.57-0.690.740.540.760.88
0.680.390.440.430.770.46-0.33-0.30.410.420.580.740.53-0.470.710.390.670.420.720.3-0.470.740.210.780.53
0.610.430.460.420.60.59-0.620.040.120.670.730.450.34-0.170.370.410.390.50.45-0.04-0.170.540.21-0.040.5
0.680.590.60.630.690.50.02-0.660.740.20.570.710.65-0.540.830.580.840.530.720.65-0.540.760.78-0.040.66
0.890.910.980.970.810.56-0.29-0.810.880.590.860.840.76-0.570.880.950.910.870.850.79-0.570.880.530.50.66
Click cells to compare fundamentals

Regenxbio Account Relationship Matchups

Regenxbio fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets497.9M708.2M1.1B833.3M574.0M487.0M
Short Long Term Debt Total11.3M72.7M86.7M94.8M89.3M50.0M
Other Current Liab21.5M62.2M100.9M89.4M93.2M97.9M
Total Current Liabilities33.7M81.4M130.5M130.4M130.3M136.8M
Total Stockholder Equity450.2M377.8M764.3M516.2M311.7M348.3M
Net Debt(58.2M)(265.8M)(258.5M)(2.2M)54.8M57.5M
Retained Earnings(177.8M)(289.1M)(161.2M)(441.6M)(705.0M)(669.8M)
Accounts Payable6.4M10.6M11.4M27.2M22.8M23.9M
Cash69.5M338.4M345.2M97.0M34.5M32.8M
Non Current Assets Total152.9M177.0M595.1M417.3M239.0M200.1M
Cash And Short Term Investments296.2M475.7M457.4M364.6M275.3M255.6M
Net Receivables38.1M43.0M32.4M28.1M26.3M18.3M
Common Stock Shares Outstanding36.7M37.3M43.9M43.2M43.7M33.3M
Liabilities And Stockholders Equity497.9M708.2M1.1B833.3M574.0M487.0M
Other Current Assets4.2M12.5M28.9M23.3M33.4M35.0M
Other Stockholder Equity627.8M667.2M928.1M973.1M1.0B551.6M
Total Liab47.7M330.4M349.6M317.1M262.2M138.7M
Total Current Assets345.0M531.2M518.8M416.0M335.0M286.9M
Accumulated Other Comprehensive Income205K(360K)(2.6M)(15.4M)(4.4M)(4.2M)
Net Tangible Assets450.2M377.8M764.3M516.2M593.6M386.3M
Non Currrent Assets Other10.0M9.9M10.7M9.9M7.5M8.4M
Other Assets10.0M8.8M1.1B9.9M11.4M10.8M
Short Term Investments226.7M137.3M112.2M267.7M240.7M168.1M
Inventory6.5M10.5M18.8M13.9M16.0M16.8M
Long Term Investments103.8M50.1M394.2M200.6M38.9M36.9M
Property Plant Equipment39.1M56.5M192.5M206.8M237.8M249.7M
Other Liab5.2M178.8M134.2M97.8M112.5M58.5M
Property Plant And Equipment Net39.1M120.3M192.5M206.8M192.6M98.2M
Retained Earnings Total Equity(83.0M)(177.8M)(289.1M)(161.2M)(145.1M)(152.4M)
Non Current Liabilities Total14.0M249.0M219.1M186.6M132.0M99.8M
Capital Surpluse592.6M627.8M667.2M928.1M1.1B586.6M
Property Plant And Equipment Gross39.1M120.3M192.5M206.8M249.8M262.3M
Net Invested Capital450.2M377.8M764.3M516.2M311.7M489.0M
Net Working Capital311.4M449.8M388.4M285.5M204.7M331.4M
Capital Lease Obligations11.3M72.7M86.7M94.8M89.3M66.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Regenxbio Stock Analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.